Juvenile Idiopathic Arthritis News and Research

RSS

Juvenile idiopathic arthritis (JIA) is the name given to a group of conditions characterized by joint inflammation or arthritis, occurring first before the age of 16.

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Gene expression differences could bring better classification and treatment of juvenile arthritis

Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). Eventually such findings could enable doctors to target more aggressive treatment to children at risk of more severe arthritis, while those likely to have milder disease could be spared the stronger treatments that carry a greater risk of side effects. The researchers were supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health.

29 Jun 2009

FDA forces manufacturers of TNF-blockers to highlight risk of fungal infections

The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.

5 Sep 2008

Foot orthoses reduce foot pain caused by arthritis

Custom-made insoles known as foot orthoses can reduce foot pain caused by arthritis, overly prominent big toe joints and highly arched feet, a new systematic review shows.

16 Jul 2008

Arthritis drugs used in children to be investigated because of cancer link

Authorities in the United States are investigating certain types of drugs used to treat arthritis and other conditions.

5 Jun 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

NICE backs use of Enbrel and Raptiva to treat severe psoriasis

NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.

26 Jul 2006

Study of fetal DNA in serum and disease activity during pregnancy in women with inflammatory arthritis

During pregnancy, women with inflammatory arthritis usually experience disease improvement or even remission, while a disease flare regularly occurs within 3 to 4 months after delivery.

27 Jun 2006

$Childhood arthritis increases the risk of fractures$

Childhood arthritis increases the risk of fractures

Childhood arthritis increases the risk of fractures, particularly during adolescence, according to a large study of British patient records. The researchers say that more targeted treatments promoting bone health would benefit patients with childhood-onset arthritis throughout their lifespan.

8 May 2006

Specific guidelines for treating juvenile idiopathic arthritis

A study published by the Cleveland Clinic and The Hospital for Sick Children (SickKids) provides the medical community for the first time with specific guidelines for treating juvenile idiopathic arthritis (JIA), previously known as juvenile rheumatoid arthritis (JRA), a condition that affects approximately one in every 1,000 children.

4 Oct 2005